Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/20703Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Mavridis, A. K. | en |
| dc.contributor.author | Tsiara, S. | en |
| dc.contributor.author | Makis, A. | en |
| dc.contributor.author | Chaidos, A. | en |
| dc.contributor.author | Christou, L. | en |
| dc.contributor.author | Seferiadis, K. | en |
| dc.contributor.author | Bourantas, K. L. | en |
| dc.date.accessioned | 2015-11-24T19:09:26Z | - |
| dc.date.available | 2015-11-24T19:09:26Z | - |
| dc.identifier.issn | 0392-9078 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/20703 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Aged, 80 and over | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Interleukins/*blood | en |
| dc.subject | Leukemia, Lymphocytic, Chronic, B-Cell/*blood/diagnosis/metabolism | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Prognosis | en |
| dc.subject | Tumor Markers, Biological/*blood | en |
| dc.subject | Tumor Necrosis Factor-alpha/*metabolism | en |
| dc.subject | beta 2-Microglobulin/*metabolism | en |
| dc.title | Interleukins, TNF-alpha and beta-2M in patients with B cell chronic lymphocytic leukemia | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/10089066 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1998 | - |
| heal.abstract | In order to investigate the possible existence of a prognostic factor for B cell chronic lymphocytic leukemia (B-CLL), we determined the serum levels of TNF-alpha, IL-1a, IL-1b, IL-2, sIL-2R, IL-6, IL-10 and beta-2M in 20 patients. We observed significant changes in sIL-2R and beta-2M levels, whereas in all stages of disease, TNF-alpha and other interleukins exhibited only mild changes. An excellent correlation between sIL-2R and beta-2M levels and disease activity wes reported. Patients with aggressive disease (Rai stages III and IV and Richter's syndrome) had increased levels. Patients who responded to therapy and with improved clinical status had decreased sIL-2R and beta-2M levels. However, patients with progressive disease and no response to therapy were associated with increased levels of sIL-2R and beta-2M. In conclusions, as serum levels of sIL-2R and beta-2M are increased in the aggressive stages of B-CLL, they may be used as reliable markers for monitoring B-CLL activity, showing response to treatment and early relapse and/or disease progression. | en |
| heal.journalName | J Exp Clin Cancer Res | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
